These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 20167189)
1. Do incretin-based therapies cause acute pancreatitis? Olansky L J Diabetes Sci Technol; 2010 Jan; 4(1):228-9. PubMed ID: 20167189 [TBL] [Abstract][Full Text] [Related]
2. Incretin-based therapies: facing the realities of benefits versus side effects. Lebovitz HE Diabetes Technol Ther; 2013 Nov; 15(11):909-13. PubMed ID: 24111860 [No Abstract] [Full Text] [Related]
3. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials. Nauck MA; Meier JJ; Schmidt WE Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752 [No Abstract] [Full Text] [Related]
4. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis? Olansky L Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512 [No Abstract] [Full Text] [Related]
5. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714 [TBL] [Abstract][Full Text] [Related]
6. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Giorda CB; Nada E; Tartaglino B; Marafetti L; Gnavi R Diabetes Obes Metab; 2014 Nov; 16(11):1041-7. PubMed ID: 24702687 [TBL] [Abstract][Full Text] [Related]
7. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan. Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712 [TBL] [Abstract][Full Text] [Related]
8. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. Montvida O; Green JB; Atherton J; Paul SK Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620 [TBL] [Abstract][Full Text] [Related]
10. Incretin-based drugs and adverse pancreatic events: almost a decade later and uncertainty remains. Azoulay L Diabetes Care; 2015 Jun; 38(6):951-3. PubMed ID: 25998285 [TBL] [Abstract][Full Text] [Related]
11. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)]. Jermendy G Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851 [TBL] [Abstract][Full Text] [Related]
12. Association of pancreatitis with glucagon-like peptide-1 agonist use. Anderson SL; Trujillo JM Ann Pharmacother; 2010 May; 44(5):904-9. PubMed ID: 20371755 [TBL] [Abstract][Full Text] [Related]
13. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Wang T; Wang F; Gou Z; Tang H; Li C; Shi L; Zhai S Diabetes Obes Metab; 2015 Jan; 17(1):32-41. PubMed ID: 25200423 [TBL] [Abstract][Full Text] [Related]
14. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Singh AK; Gangopadhyay KK; Singh R Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106 [TBL] [Abstract][Full Text] [Related]
15. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601 [TBL] [Abstract][Full Text] [Related]
16. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis. Schectman J Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777 [No Abstract] [Full Text] [Related]
17. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098. Smits MM; Muskiet MH; Tonneijck L; van Raalte DH Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231 [No Abstract] [Full Text] [Related]
18. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098. Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232 [No Abstract] [Full Text] [Related]
19. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Giorda CB; Sacerdote C; Nada E; Marafetti L; Baldi I; Gnavi R Endocrine; 2015 Mar; 48(2):461-71. PubMed ID: 25146552 [TBL] [Abstract][Full Text] [Related]
20. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Roshanov PS; Dennis BB Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]